公开(公告)号：US07279593B2

公开(公告)日：2007-10-09

申请号：US10485849

申请日：2002-08-13

申请人： Johan Malm ,  Peter Brandt ,  Karin Edvinsson ,  Konrad Koehler ,  Andrei Sanin ,  Sandra Gordon

发明人： Johan Malm ,  Peter Brandt ,  Karin Edvinsson ,  Konrad Koehler ,  Andrei Sanin ,  Sandra Gordon

IPC分类号： C07C69/76 ,  A61K31/085

CPC分类号： C07D213/30 ,  A61K31/192 ,  A61K31/425 ,  A61K31/44 ,  A61K31/603 ,  C07C59/68 ,  C07C65/26 ,  C07D241/12

摘要： This invention relates to novel compounds which are thyroid receptor ligands, preferably antagonists, and to methods for using such compounds in the treatment of cardiac and metabolic disorders, such as cardiac arrhythmias, thyrotoxicosis, subclinical hyperthyrodism and liver diseases.

摘要翻译： 本发明涉及作为甲状腺受体配体，优选拮抗剂的新化合物，以及使用这些化合物治疗心脏和代谢紊乱如心律失常，甲状腺毒症，亚临床甲状腺功能亢进和肝脏疾病的方法。

公开(公告)号：US20050107347A1

公开(公告)日：2005-05-19

申请号：US10485849

申请日：2002-08-13

申请人： Johan Malm ,  Peter Brandt ,  Karin Edvinsson ,  Konrad Koehler ,  Andrei Sanin ,  Sandra Gordon

发明人： Johan Malm ,  Peter Brandt ,  Karin Edvinsson ,  Konrad Koehler ,  Andrei Sanin ,  Sandra Gordon

IPC分类号： C07D277/24 ,  A61K31/192 ,  A61K31/195 ,  A61K31/425 ,  A61K31/426 ,  A61K31/44 ,  A61K31/496 ,  A61K31/603 ,  A61P1/16 ,  A61P3/00 ,  A61P5/14 ,  A61P9/00 ,  A61P9/06 ,  A61P17/00 ,  A61P17/06 ,  A61P37/08 ,  A61P43/00 ,  C07C59/68 ,  C07C65/24 ,  C07C65/26 ,  C07D213/30 ,  C07D241/12 ,  C07F9/28 ,  A61K31/198 ,  A61K31/66

CPC分类号： C07D213/30 ,  A61K31/192 ,  A61K31/425 ,  A61K31/44 ,  A61K31/603 ,  C07C59/68 ,  C07C65/26 ,  C07D241/12

摘要： This invention relates to novel compounds which are thyroid receptor ligands, preferably antagonists, and to methods for using such compounds in the treatment of cardiac and metabolic disorders, such as cardiac arrhythmias, thyrotoxicosis, subclinical hyperthyrodism and liver diseases.

摘要翻译： 本发明涉及作为甲状腺受体配体，优选拮抗剂的新化合物，以及使用这些化合物治疗心脏和代谢紊乱如心律失常，甲状腺毒症，亚临床甲状腺功能亢进和肝脏疾病的方法。

公开(公告)号：US08263659B2

公开(公告)日：2012-09-11

申请号：US12469791

申请日：2009-05-21

申请人： Denis E. Ryono ,  Jon J. Hangeland ,  Todd J. Friends ,  Tamara Dejneka ,  Pratik Devasthale ,  Yolanda V. Caringal ,  Minsheng Zhang ,  Arthur M. P. Doweyko ,  Johan Malm ,  Andrei Sanin

发明人： Denis E. Ryono ,  Jon J. Hangeland ,  Todd J. Friends ,  Tamara Dejneka ,  Pratik Devasthale ,  Yolanda V. Caringal ,  Minsheng Zhang ,  Arthur M. P. Doweyko ,  Johan Malm ,  Andrei Sanin

IPC分类号： A61K31/19 ,  A61K31/165 ,  C07C321/00 ,  C07C229/00 ,  C07C59/00

CPC分类号： C07C311/46 ,  A61K31/4439 ,  A61K31/662 ,  A61K45/06 ,  C07C43/29 ,  C07C43/295 ,  C07C59/68 ,  C07C59/72 ,  C07C65/24 ,  C07C65/26 ,  C07C69/16 ,  C07C69/736 ,  C07C69/94 ,  C07C205/38 ,  C07C217/58 ,  C07C233/29 ,  C07C235/34 ,  C07C235/42 ,  C07C235/46 ,  C07C235/52 ,  C07C235/60 ,  C07C235/62 ,  C07C235/64 ,  C07C311/37 ,  C07C2601/02 ,  C07C2601/14 ,  C07C2602/08 ,  C07C2603/18 ,  C07D213/30 ,  C07D239/26 ,  C07D257/04 ,  C07D263/14 ,  C07D263/32 ,  C07D277/24 ,  C07D285/06 ,  C07D307/42 ,  C07D307/52 ,  C07D307/87 ,  C07D317/58 ,  C07D317/60 ,  C07D333/32 ,  C07F9/306 ,  C07F9/3241 ,  C07F9/4056 ,  A61K2300/00

摘要： A method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T3 regulated gene, wherein a compound as described in the general formula I below is administered in a therapeutically effective amount:

摘要翻译： 提供了一种用于预防，抑制或治疗与代谢功能障碍相关或与T3调节基因的表达有关的疾病或病症的方法，其中以治疗有效量施用下述通式I中所述的化合物：

公开(公告)号：US07557143B2

公开(公告)日：2009-07-07

申请号：US10826100

申请日：2004-04-15

申请人： Denis E. Ryono ,  Jon J. Hangeland ,  Todd J. Friends ,  Tamara Dejneka ,  Pratik Devasthale ,  Yolanda V. Caringal ,  Minsheng Zhang ,  Arthur M. P. Doweyko ,  Johan Malm ,  Andrei Sanin

发明人： Denis E. Ryono ,  Jon J. Hangeland ,  Todd J. Friends ,  Tamara Dejneka ,  Pratik Devasthale ,  Yolanda V. Caringal ,  Minsheng Zhang ,  Arthur M. P. Doweyko ,  Johan Malm ,  Andrei Sanin

IPC分类号： A61K31/165 ,  A61K31/19 ,  C07C239/00 ,  C07C325/00 ,  C07C229/00 ,  C07C59/00

CPC分类号： C07C311/46 ,  A61K31/4439 ,  A61K31/662 ,  A61K45/06 ,  C07C43/29 ,  C07C43/295 ,  C07C59/68 ,  C07C59/72 ,  C07C65/24 ,  C07C65/26 ,  C07C69/16 ,  C07C69/736 ,  C07C69/94 ,  C07C205/38 ,  C07C217/58 ,  C07C233/29 ,  C07C235/34 ,  C07C235/42 ,  C07C235/46 ,  C07C235/52 ,  C07C235/60 ,  C07C235/62 ,  C07C235/64 ,  C07C311/37 ,  C07C2601/02 ,  C07C2601/14 ,  C07C2602/08 ,  C07C2603/18 ,  C07D213/30 ,  C07D239/26 ,  C07D257/04 ,  C07D263/14 ,  C07D263/32 ,  C07D277/24 ,  C07D285/06 ,  C07D307/42 ,  C07D307/52 ,  C07D307/87 ,  C07D317/58 ,  C07D317/60 ,  C07D333/32 ,  C07F9/306 ,  C07F9/3241 ,  C07F9/4056 ,  A61K2300/00

摘要： Thyroid receptor ligands are provided which have the general formula I wherein: R1 is R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, provided that at least one of R2 and R3 is other than hydrogen; R4 is R5 and R6 are the same or different and are selected from hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, aralkyl or heteroaralkyl. R7 is aryl, heteroaryl, alkyl, aralkyl, or heteroaralkyl; R8 is aryl, heteroaryl, or cycloalkyl; R9 is R7 or hydrogen; R10 is hydrogen, halogen, cyano or alkyl; R11 and R12 are each independently selected from the group consisting of hydrogen, halogen, alkoxy, hydroxy (—OH) cyano, and alkyl; R13 is carboxylic acid (COOH) or esters thereof, phosphonic and phosphinic acid or esters thereof, sulfonic acid, tetrazole, hydroxamic acid, thiazolidinedione, acylsulfonamide, or other carboxylic acid surrogates known in the art; R14 and R15 may be the same or different and are selected from hydrogen and alkyl, or R14 and R15 may be joined together forming a chain of 2 to 5 methylene groups [—(CH2)m-, m=2, 3, 4 or 5], thus forming 3- to 6-membered cycloalkyl rings; R16 is hydrogen or alkyl of 1 to 4 carbons; R17 and R18 are the same or different and selected from hydrogen, halogen and alkyl; n is 0 or an integer from 1 to 4; X is oxygen (—O—), sulfur (—S—), sulfonyl (—SO2—), sulfenyl (—SO—) selenium (—Se—), carbonyl (—CO—), amino (—NH—) or methylene (—CH2-); wherein the substituents are as described herein. In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.

摘要翻译： 提供具有通式I的甲状腺受体配体，其中：R 1是R 2和R 3相同或不同，是氢，卤素，1至4个碳的烷基或3至5个碳原子的环烷基，条件是R2中的至少一个 并且R 3不是氢; R 4是R 5和R 6相同或不同，并且选自氢，芳基，杂芳基，烷基，环烷基，芳烷基或杂芳烷基。 R7是芳基，杂芳基，烷基，芳烷基或杂芳烷基; R8是芳基，杂芳基或环烷基; R9为R7或氢; R 10是氢，卤素，氰基或烷基; R 11和R 12各自独立地选自氢，卤素，烷氧基，羟基（-OH）氰基和烷基; R13是羧酸（COOH）或其酯，膦酸和次膦酸或其酯，磺酸，四唑，异羟肟酸，噻唑烷二酮，酰基磺酰胺或本领域已知的其它羧酸替代物; R 14和R 15可以相同或不同，并且选自氢和烷基，或者R 14和R 15可以连接在一起形成2至5个亚甲基 - [ - （CH 2）m - ，m = 2,3,4或 5]，从而形成3-至6-元环烷基环; R16是氢或1至4个碳的烷基; R 17和R 18相同或不同，选自氢，卤素和烷基; n为0或1至4的整数; X是氧（-O-），硫（-S-），磺酰基（-SO 2 - ），亚磺酰基（-SO-），硒（-Se-），羰基（-CO-），氨基（-NH-） 或亚甲基（-CH2-）; 其中取代基如本文所述。 此外，提供了一种用于预防，抑制或治疗与代谢功能障碍相关或依赖于T3调节基因的表达的疾病或病症的方法，其中如上所述的化合物以治疗有效量施用。

公开(公告)号：US20050004184A1

公开(公告)日：2005-01-06

申请号：US10826100

申请日：2004-04-15

申请人： Denis Ryono ,  Jon Hangeland ,  Todd Friends ,  Tamara Dejneka ,  Pratik Devasthale ,  Yolanda Caringal ,  Minsheng Zhang ,  Arthur Doweyko ,  Johan Malm ,  Andrei Sanin

发明人： Denis Ryono ,  Jon Hangeland ,  Todd Friends ,  Tamara Dejneka ,  Pratik Devasthale ,  Yolanda Caringal ,  Minsheng Zhang ,  Arthur Doweyko ,  Johan Malm ,  Andrei Sanin

IPC分类号： A61K20060101 ,  A61K31/16 ,  A61K31/165 ,  A61K31/19 ,  A61K31/277 ,  A61K31/421 ,  A61K31/44 ,  A61K47/00 ,  C07C205/00 ,  C07C235/20 ,  C07C255/49 ,  C07C381/00

CPC分类号： C07C311/46 ,  A61K31/4439 ,  A61K31/662 ,  A61K45/06 ,  C07C43/29 ,  C07C43/295 ,  C07C59/68 ,  C07C59/72 ,  C07C65/24 ,  C07C65/26 ,  C07C69/16 ,  C07C69/736 ,  C07C69/94 ,  C07C205/38 ,  C07C217/58 ,  C07C233/29 ,  C07C235/34 ,  C07C235/42 ,  C07C235/46 ,  C07C235/52 ,  C07C235/60 ,  C07C235/62 ,  C07C235/64 ,  C07C311/37 ,  C07C2601/02 ,  C07C2601/14 ,  C07C2602/08 ,  C07C2603/18 ,  C07D213/30 ,  C07D239/26 ,  C07D257/04 ,  C07D263/14 ,  C07D263/32 ,  C07D277/24 ,  C07D285/06 ,  C07D307/42 ,  C07D307/52 ,  C07D307/87 ,  C07D317/58 ,  C07D317/60 ,  C07D333/32 ,  C07F9/306 ,  C07F9/3241 ,  C07F9/4056 ,  A61K2300/00

摘要： Thyroid receptor ligands are provided which have the general formula I wherein: R1 is R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, provided that at least one of R2 and R3 is other than hydrogen; R4 is R5 and R6 are the same or different and are selected from hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, aralkyl or heteroaralkyl. R7 is aryl, heteroaryl, alkyl, aralkyl, or heteroaralkyl; R8 is aryl, heteroaryl, or cycloalkyl; R9 is R7 or hydrogen; R10 is hydrogen, halogen, cyano or alkyl; R11 and R12 are each independently selected from the group consisting of hydrogen, halogen, alkoxy, hydroxy (—OH) cyano, and alkyl; R13 is carboxylic acid (COOH) or esters thereof, phosphonic and phosphinic acid or esters thereof, sulfonic acid, tetrazole, hydroxamic acid, thiazolidinedione, acylsulfonamide, or other carboxylic acid surrogates known in the art; R14 and R15 may be the same or different and are selected from hydrogen and alkyl, or R14 and R15 may be joined together forming a chain of 2 to 5 methylene groups [—(CH2)m-, m=2, 3, 4 or 5], thus forming 3- to 6-membered cycloalkyl rings; R16 is hydrogen or alkyl of 1 to 4 carbons; R17 and R18 are the same or different and selected from hydrogen, halogen and alkyl; n is 0 or an integer from 1 to 4; X is oxygen (—O—), sulfur (—S—), sulfonyl (—SO2—), sulfenyl (—SO—) selenium (—Se—), carbonyl (—CO—), amino (—NH—) or methylene (—CH2-); wherein the substituents are as described herein. In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.

摘要翻译： 提供具有通式I的甲状腺受体配体，其中：R 1是R 2和R 3相同或不同，是氢，卤素，1至4个碳的烷基或3至5个碳原子的环烷基，条件是R2中的至少一个 并且R 3不是氢; R 4是R 5和R 6相同或不同，并且选自氢，芳基，杂芳基，烷基，环烷基，芳烷基或杂芳烷基。 R7是芳基，杂芳基，烷基，芳烷基或杂芳烷基; R8是芳基，杂芳基或环烷基; R9为R7或氢; R 10是氢，卤素，氰基或烷基; R 11和R 12各自独立地选自氢，卤素，烷氧基，羟基（-OH）氰基和烷基; R13是羧酸（COOH）或其酯，膦酸和次膦酸或其酯，磺酸，四唑，异羟肟酸，噻唑烷二酮，酰基磺酰胺或本领域已知的其它羧酸替代物; R 14和R 15可以相同或不同，并且选自氢和烷基，或者R 14和R 15可以连接在一起形成2至5个亚甲基 - [ - （CH 2）m - ，m = 2,3,4或 5]，从而形成3-至6-元环烷基环; R16是氢或1至4个碳的烷基; R 17和R 18相同或不同，选自氢，卤素和烷基; n为0或1至4的整数; X是氧（-O-），硫（-S-），磺酰基（-SO 2 - ），亚磺酰基（-SO-）硒（-Se-），羰基（-CO-），氨基（-NH-）或 亚甲基（-CH 2 - ） 其中取代基如本文所述。 此外，提供了一种用于预防，抑制或治疗与代谢功能障碍相关或依赖于T3调节基因的表达的疾病或病症的方法，其中如上所述的化合物以治疗有效量施用。

公开(公告)号：US20100298276A1

公开(公告)日：2010-11-25

申请号：US12469791

申请日：2009-05-21

申请人： Denis E. Ryono ,  Jon J. Hangeland ,  Todd J. Friends ,  Tamara Dejneka ,  Pratik Devasthale ,  Yolanda V. Caringal ,  Minsheng Zhang ,  Arthur M.P. Doweyko ,  Johan Malm ,  Andrei Sanin

发明人： Denis E. Ryono ,  Jon J. Hangeland ,  Todd J. Friends ,  Tamara Dejneka ,  Pratik Devasthale ,  Yolanda V. Caringal ,  Minsheng Zhang ,  Arthur M.P. Doweyko ,  Johan Malm ,  Andrei Sanin

IPC分类号： A61K31/662 ,  C07F9/02 ,  A61P3/10

CPC分类号： C07C311/46 ,  A61K31/4439 ,  A61K31/662 ,  A61K45/06 ,  C07C43/29 ,  C07C43/295 ,  C07C59/68 ,  C07C59/72 ,  C07C65/24 ,  C07C65/26 ,  C07C69/16 ,  C07C69/736 ,  C07C69/94 ,  C07C205/38 ,  C07C217/58 ,  C07C233/29 ,  C07C235/34 ,  C07C235/42 ,  C07C235/46 ,  C07C235/52 ,  C07C235/60 ,  C07C235/62 ,  C07C235/64 ,  C07C311/37 ,  C07C2601/02 ,  C07C2601/14 ,  C07C2602/08 ,  C07C2603/18 ,  C07D213/30 ,  C07D239/26 ,  C07D257/04 ,  C07D263/14 ,  C07D263/32 ,  C07D277/24 ,  C07D285/06 ,  C07D307/42 ,  C07D307/52 ,  C07D307/87 ,  C07D317/58 ,  C07D317/60 ,  C07D333/32 ,  C07F9/306 ,  C07F9/3241 ,  C07F9/4056 ,  A61K2300/00

摘要： Thyroid receptor ligands are provided which have the general formula I wherein: R1 is R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, provided that at least one of R2 and R3 is other than hydrogen; R4 is R5 and R6 are the same or different and are selected from hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, aralkyl or heteroaralkyl. R7 is aryl, heteroaryl, alkyl, aralkyl, or heteroaralkyl; R8 is aryl, heteroaryl, or cycloalkyl; R9 is R7 or hydrogen; R10 is hydrogen, halogen, cyano or alkyl; R11 and R12 are each independently selected from the group consisting of hydrogen, halogen, alkoxy, hydroxy (—OH) cyano, and alkyl; R13 is carboxylic acid (COOH) or esters thereof, phosphonic and phosphinic acid or esters thereof, sulfonic acid, tetrazole, hydroxamic acid, thiazolidinedione, acylsulfonamide, or other carboxylic acid surrogates known in the art; R14 and R15 may be the same or different and are selected from hydrogen and alkyl, or R14 and R15 may be joined together forming a chain of 2 to 5 methylene groups [—(CH2)m-, m=2, 3, 4 or 5], thus forming 3- to 6-membered cycloalkyl rings; R16 is hydrogen or alkyl of 1 to 4 carbons; R17 and R18 are the same or different and selected from hydrogen, halogen and alkyl; n is 0 or an integer from 1 to 4; X is oxygen (—O—), sulfur (—S—), sulfonyl (—SO2—), sulfenyl (—SO—) selenium (—Se—), carbonyl (—CO—), amino (—NH—) or methylene (—CH2-); wherein the substituents are as described herein. In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.

公开(公告)号：US20090143455A1

公开(公告)日：2009-06-04

申请号：US12083782

申请日：2006-10-19

申请人： Benjamin Pelcman ,  Andrei Sanin ,  Peter Nilsson ,  Thomas Boesen ,  Stine Byskov Vogensen ,  Hasse Kromann ,  Thomas Groth

发明人： Benjamin Pelcman ,  Andrei Sanin ,  Peter Nilsson ,  Thomas Boesen ,  Stine Byskov Vogensen ,  Hasse Kromann ,  Thomas Groth

IPC分类号： A61K31/415 ,  C07D231/10 ,  A61P29/00 ,  A61P11/00 ,  A61P1/00 ,  A61P9/00 ,  A61P17/00 ,  A61P19/02 ,  A61P25/00 ,  A61P35/00

CPC分类号： C07D231/12 ,  C07D231/14 ,  C07D231/16

摘要： There is provided compounds of formula I, wherein R1, R2, X1, X2 and n have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.

摘要翻译： 提供式I化合物，其中R1，R2，X1，X2和n具有本说明书中给出的含义及其药学上可接受的盐，该化合物可用于治疗脂氧合酶活性抑制的疾病 （例如15-脂氧合酶）是期望和/或需要的，特别是在治疗炎症中。

公开(公告)号：US20070225318A1

公开(公告)日：2007-09-27

申请号：US11663208

申请日：2005-09-19

申请人： Peter Nilsson ,  Andrei Sanin ,  Benjamin Pelcman

发明人： Peter Nilsson ,  Andrei Sanin ,  Benjamin Pelcman

IPC分类号： A61K31/4155 ,  A61K31/4375 ,  A61K31/47 ,  C07D215/00 ,  C07D231/10 ,  C07D471/04

CPC分类号： C07D471/04 ,  C07D231/14 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D487/14 ,  C07D491/04 ,  C07D491/056 ,  C07D493/04 ,  C07D495/04

摘要： There is provided compounds of formula (I), wherein R1, R2, Ra and Rb have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.

摘要翻译： 提供式（I）化合物，其中R 1，R 2，R a和R b都是 具有说明书中给出的含义及其药学上可接受的盐，该化合物可用于治疗期望和/或需要抑制脂氧合酶（例如，15-脂肪氧合酶）的活性的疾病，特别是在治疗中 的炎症。

公开(公告)号：US20090186918A1

公开(公告)日：2009-07-23

申请号：US12084400

申请日：2006-10-27

申请人： Benjamin Pelcman ,  Andrei Sanin ,  Peter Nilsson ,  Hasse Kromann

发明人： Benjamin Pelcman ,  Andrei Sanin ,  Peter Nilsson ,  Hasse Kromann

IPC分类号： A61K31/4709 ,  C07D401/12 ,  A61K31/4439

CPC分类号： C07D417/14 ,  C07D249/04 ,  C07D401/12 ,  C07D403/12

摘要： There is provided compounds of formula (I) wherein W is an optionally substituted aryl or heteroaryl group, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.

摘要翻译： 提供了其中W是任选取代的芳基或杂芳基的式（I）化合物及其药学上可接受的盐，该化合物可用于治疗其中抑制脂氧合酶活性的疾病（例如，15-脂氧合酶 ）是期望和/或需要的，特别是在炎症的治疗中。

公开(公告)号：US20090088463A1

公开(公告)日：2009-04-02

申请号：US12084426

申请日：2006-10-30

申请人： Benjamin Pelcman ,  Andrei Sanin ,  Peter Nilsson

发明人： Benjamin Pelcman ,  Andrei Sanin ,  Peter Nilsson

IPC分类号： A61K31/415 ,  C07D231/14 ,  A61P29/00

CPC分类号： C07D231/14

摘要： There is provided compounds of formula (I), wherein X1 to X5 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.

摘要翻译： 提供式（I）化合物，其中X1至X5具有说明书中给出的含义及其药学上可接受的盐，该化合物可用于治疗脂氧合酶活性抑制的疾病（例如15- 脂氧合酶）是期望和/或需要的，特别是在治疗炎症中。